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a  b  s  t  r  a  c  t
INTRODUCTION:  Choriocarcinoma  is a rare primary  germ  cell  tumour  of  the  ovary  composed  of  cyto-
and  syncytotrophoblast  cells.  Most  of the  choriocarcinomas  are  normally  arising  in  the  gestational  tro-
phoblast,  gonads  and, less  frequently,  mediastinum,  pineal  gland  and  retroperitoneum.
PRESENTATION  OF  CASE:  We  report  a  case  of primary  choriocarcinoma  of renal  artery  causing  secondary
renovascular  hypertension  in  a 28  years  old  woman  of reproductive  age,  presenting  with  abdominal  pain,
minimal  vaginal  bleeding  and  a  delayed  menstrual  period.
DISCUSSION:  Non-gestational  choriocarcinomas,  are  histologically  related  to  the  pregnancy  related  ges-
tational choriocarcinomas.  These  two subtypes  may  have  to  be differentiated  according  the clinical  and
radiological  ﬁndings  and  DNA analysis  may  be used  for this  purpose  as well.  In  many  studies,  authorsecondary renovascular hypertension
regnancy of unknown location
have  stated  that nongestational  choriocarcinoma  diagnosis  could  be implemented  in  situations  where
the  presence  of  a pregnancy  could  not  be  considered  like  the  prepubertal  period.
CONCLUSION:  Choriocarcinoma  should  as  well  be considered  among  the  possibilities  in the differential
diagnosis  of the  causes  for secondary  hypertension,  especially  within  a picture  of pregnancy  of unknown
location,  albeit  being  one  of  the  rarest.
© 2014  Published  by Elsevier  Ltd.  on  behalf of Surgical  Associates  Ltd.  This  is an  open  access  article
he  CCunder  t
. Introduction
Choriocarcinoma is a rare primary germ cell tumour of the ovary
omposed of cyto- and syncytotrophoblast cells.1 Most of the ges-
ational choriocarcinomas stem from the uterine cavity. These may
how up as consequences of normal or abnormal gestations. The
ncidence in the United States is within a rate of 110–120 per
00,000 pregnancies.2 Non-gestational choriocarcinomas may  be
resented as a component of a mixed germ cell tumours of the
vary or as pure choriocarcinomas. Non-gestational choriocarci-
omas of the ovary comprise a very small percentage of all the
varian carcinomas (0.6%); and extremely rarely observed as ‘pure
horiocarcinoma of the ovary’.3 Extragonadal nongestational chori-
carcinomas may  be misdiagnosed as ‘gestational choriocarcinoma
etastasis’; and in many patients, the prognosis is worsened due
o delayed diagnosis. In performing the differential diagnosis for
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postmenarcheal cases gestational choriocarcinoma metastasis
must be ruled out.1 Due to their rarity, information about their
clinical behaviour, diagnosis and treatment is limited.3
2. Case report
A 28 years old woman applied to the emergency section of our
hospital with lower pelvic pain, ﬂank pain, minimal vaginal bleed-
ing and a delayed menstrual period. She had nothing remarkable
in her obstetrical and medical histories. She had 2 previous vagi-
nal deliveries with the latest being 4 years prior to the time being.
In the initial evaluation, her general condition was  stable, blood
pressure (100/60 mmHg) and pulse values (90 beats per minute)
normal, body temperature: 37.2 ◦C. and had a minimal abdom-
inal guarding. Speculum examination revealed no more than a
minimal extra uterine oozing. Transvaginal sonography revealed
normal pelvic organs and endometrial thickness as 13 mm.  Initial
lab ﬁndings were within normal limits. Blood electrolyte levels,
hepatic and renal function tests were normal. (AST: 11 mIU/dl;
ALT: 6 mIU/dl; ALP: 109 mIU/dl; LDH: 141 mIU/dl; total bilirubin:
0.27 mg/dl; total protein: 6.86gm/dl; urea: 17 mg/dl; creatinine:
0.72 mg/dl). Blood CRP (C-reactive protein) level was  278 mg/l. The
s Ltd. This is an open access article under the CC BY-NC-ND license
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wig. 1. A whole abdominal CT imaging revealed a mass totally occluding the left
enal artery and reaching the abdominal aorta.
-human chorionic gonadotropin (-hCG) was 344.4 mIU/dl. The
atient was initially hospitalized with a preliminary diagnosis of
regnancy of unknown location (ectopic pregnancy?). In the dif-
erential diagnosis, complete abortion and abortus imminens of
n early gestation were considered. Two days later, following a
lood -hCG level of 445 mIU/ml, an endometrial sampling was
erformed being reported as proliferative phase endometrium. A
ingle cure of 50 mg  methotrexate (MTX) applied. On the 4th and
he 7th days, the -hCG levels were 460 mIU/ml and 412 mIU/ml,
espectively. The response was suboptimal. The condition was dis-
ussed with the patient and a laparoscopy was performed revealing
ompletely normal pelvic ﬁndings. Due to the persisting high blood
-hCG levels, 3 cycles of double dose 75 mg  MTX  (on day 0 and
ay 4) cures were carried out. -hCG levels were measured on
he 4th and 7th day of each treatment cycle; with results: 434,
47, 701, 770, 1131, 1275 mIU/ml, respectively. Cranial and lower
bdominal magnetic resonance imagings (MRI) were reported as
ormal. Despite weekly MTX  therapies, the blood -hCG levels
ere as high as 47915 mIU/ml; hence the patient, accepted as
MTX therapy resistant’ and the decision made to institute the mul-
iagent EMA/CO protocol as 12 cures, every 14 days (etoposide
70 mg/m2/d, MTX  500 mg/m2/d, actinomycine 0.5 mg/d, calcium
olinate 15 mg  twice daily, cyclophosphamide 1000 mg/m2/d, vin-
ristine sulfate 1.4 mg/m2/d). Due to the C-reactive protein blood
evel being 278 mg/dl, Ceftriaxon (Rocephine®) 500 mg  1 × 2 and
oxiﬂoxacine (Avelox®) 400 mg  1 × 1 were started. A whole
bdominal computed tomography (CT) imaging revealed a mass
otally occluding the left renal artery and reaching the abdomi-
al aorta (As shown in Fig. 1). Static and dynamic scintigraphies
f the kidneys showed that the left kidney was totally nonfunc-
ional. The mass obstructing the renal artery was interpreted as
 thrombus and enoxaparin sodium (0.6cc × 2) was started. In
his period, the patient had a left ﬂank pain not responding to
arcotic analgesics. Doppler ultrasonographic examination could
ot view any blood ﬂow in the left renal artery or vein. Gas-
roscopic and colonoscopic images of the gastrointestinal system
ere also normal. Pheochromocytoma was ruled out by check-
ng the urinary metanephrine and catecholamine levels. Occasional
ypertensive episodes were initially treated with perindopril
 mg 1 × 1 and amlodipin 5 mg  1 × 1, afterwards. With ﬂuorine-
8-ﬂuorodeoxyglucose positron emission tomography (FDF-PET)
ypermetabolic areas were observed at the junction of the left
enal artery and the aorta at the left lateral of the abdominal aorta.
ollowing a ﬁnal -hCG blood level of 70,373 mIU/ml a diagnos-
ic laparotomy was planned for extraction of the mass obstructing
he left renal artery. During the operation, the left renal artery and
he abdominal aorta-within the segment starting from where the
eft renal artery connection, as low down to the iliac bifurcation
ere ﬁlled with thrombus (As shown in Fig. 2). Left nephrectomyFig. 2. Choriocarcinoma is seen along the left side of the abdominal aorta.
and abdominal aorta thromboendarterectomy were performed. No
intra- or postoperative complications were observed. In the gross
morphological evaluation of the nephrectomy specimen, the pelvi-
calyceal system looked normal, and no mass or mass effect was
observed in the renal parenchyma. The corticomedullary junction
was apparent. Histopathological examination revealed widespread
atrophy of the renal parenchyma, patchy sclerosis of the glomeruli
and rare ﬁbrotic foci were observed. Within the left proximal renal
artery lumen, choriocarcinoma inﬁltration of the endothelium and
an overlying thrombus was observed. Pathological examination
concluded that the tumour was not originating from the kidney.
When the whole specimen was examined, there was no tumour
observed within the renal parenchyma. Yet, accounting for the
current clinical and radiological data, the case was  diagnosed as
‘primary choriocarcinoma originating from the renal artery’. The
patient completed 12 cures of the EMA/CO multiagent chemother-
apy protocol. The -hCG blood levels regressed and within 1 year
following the operation, no hypertensive episodes or choriocarci-
noma recurrences were observed.
3. Discussion
Nongestational choriocarcinomas are a histological subtype of
germ cell tumours and in fact originate from primordial germ cells
of the ovary. These tumours display the same histomorphology
of their analogue in men, the testicular germ cell choriocarci-
noma; but its incidence is about one tenth.4 In both sexes, the
tumour may  originate the midline structures especially the ante-
rior mediastinum, the pineal gland, the suprasellar region, the
sacrococcyx; and rarely the vagina, the orbitas, the thyroid gland,
the supramandibular region, the anterior abdominal wall, the
prostate, the stomach, the liver, the brain, the bladder and the
kidneys.5–7 Still a matter of debate, the origins of the extrago-
nadal germ cell tumours have been hypothesized by 3 theories:
displacement of primitive germ cells during the migration stage
from the yolk sac ectoderm to the gonadal region; the persis-
tence of pluripotential stem cells sequestered within primitive
residual tissues during somatic development; or their malposition-
ing during the blastula or morula stages of embryogenesis.4 More
recent studies have revealed that germ cells do migrate to extrag-
onadal organs like the liver, the thymus, the bone marrow or the
brain and have the potential to be the origin of primary tumours.
Non-gestational choriocarcinomas, are histologically related to
the pregnancy related gestational choriocarcinomas. These two
subtypes may  have to be differentiated according the clinical
and radiological ﬁndings and DNA analysis may be used for this
purpose as well.1,8 The non-gestational type, may be differen-
tiated according to the absence of the paternal component or
human leucocyte antigen (HLA) subtyping in DNA polymorphism
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nalysis; however, their clinical applicability is limited. In many
tudies, authors have stated that nongestational choriocarcinoma
iagnosis could be implemented in situations where the presence
f a pregnancy could not be considered like the prepubertal period.9
n the current literature, cases which have been stated as extrag-
nadal nongestational choriocarcinomas must actually have been
estational choriocarcinomas with unidentiﬁed primaries. Also in
linical practise, most of the extragonadal nongestational cases
tated as primary pathologies have been shown to be nonges-
ational choriocarcinoma metastasis with unknown primaries.5,8
ecause the therapeutical approaches are different, it is essential
hat gestational and nongestational choriocarcinomas are differen-
iated. While the gestational choriocarcinomas respond favourably
o MTX  based chemotherapies, nongestational choriocarcinomas
ay  be resistant to these modalities and may  more favourably be
esponsive to multiagent chemotherapies.3 The case found to be
esistant to MTX  therapy was reevaluated, taking into consider-
tion the radiological, clinical and surgical ﬁndings; and decided
o be treated with the EMA/CO multiagent chemotherapy protocol
s a nongestational or gestational choriocarcinoma with unknown
rimary. Despite this, the serum -hCG levels continued to rise.
ecause most of developments in the treatment modalities of pri-
ary nongestational choriocarcinomas are stemming from the data
elated to testicular tumours, there is no standard treatment modal-
ty for the treatment of these tumours. Generally, there are 2
ccepted treatment options. The ﬁrst is to accept this tumour as
 gestational germ cell tumour and to start a single agent MTX  or a
ultiagent protocol like EMA/CO; the second option is to administer
 nongestational germ-cell tumour protocol like VAC (vincristine,
ctinomycin D, cyclophosphamide) or BEP (bleomycine, etopo-
ide, cisplatin).10 In addition to these, there are studies which
eport that treatment regimens like MAC  (methotrexate, acti-
omycin D, cyclophosphamide) or VBP (vincristine, bleomycine,
isplatin) can provide complete cure.12 Because of the rarity of
hese nongestational choriocarcinomas, the literature regarding
he chemotherapy of these tumours is still too scant and there
s no consensus. We  initially preferred the EMA/CO protocol. -
CG monitorization may  help in the assessment of the response
f choriocarcinoma to medical treatment; however, it has no use
n the differentiation of the gestational subtype from the nonges-
ational one.10 The mass originating from the renal artery which
as initially deﬁned as a thrombus was, interestingly later when
escreened with the FDG-PET was deﬁned as a possible metabol-
cally active neoplasia. A preoperative FDG-PET was performed:
iewing hypermetabolic areas in the left renal arterial lumen and
long the left side of the abdominal aorta suggesting the loca-
ions of neoplastic tissues. Against all odds, including the risk of
 systemic thromboembolism, a nephrectomy and a thromboen-
areterectomy was performed subserving both therapeutic and
eﬁnitive objectives. Eventually, as described in the previous sec-
ion, pathological examination concluded that the tumour was  not
riginating from the kidney.
An intracranial pathology had been ruled out with a cranial CT;
 primary or a secondary thoracic pathology was  as well ruled out
ith a thorax spiral CT. The FDG-PET had not shown any other
emarkable hypermetabolic foci in any other locations suggesting
hat there was no other primary. Regarding all the radiological and
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for the tumour. To our knowledge, one case of choriocarcinoma of
vascular origin, presenting with nonspeciﬁc pulmonary symptoms,
causing secondary pulmonary hypertension has been reported.11
As of the current time a choriocarcinoma originating from the renal
artery causing secondary hypertension has never been reported
in the literature. In conclusion, choriocarcinoma should as well be
considered among the possibilities in the differential diagnosis of
the primary causes for secondary hypertension especially within a
clinical picture of pregnancy of unknown location, albeit being one
of the rarest.
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